TNC: Tenascin
Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration.
- Drugs that act on it: 4
- Approved: 0
- In phases 1 to 3: 4
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on TNC, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Other 3
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Philogen S.p.A.250%
| 81C6 131I | Phase 2 | — | Other | Binding agentTenascin binding agent | 0 |
| F16IL2 | Phase 2 | Philogen S.p.A. | Other | OtherTenascin other | 0 |
| F16SIP 131I | Phase 2 | Philogen S.p.A. | Other | Binding agentTenascin binding agent | 0 |
| Tenatumomab | Phase 2 | — | Antibody | OtherTenascin other | 0 |
- Autosomal dominant nonsyndromic hearing loss0.62
- Deafness0.55
- Osteoarthritis, hip0.55
- Total hip arthroplasty0.47
- Varicose veins0.46
- Abnormality of the skeletal system0.46
- Dupuytren Contracture0.46
- Osteoarthritis0.42
- Vein disorder0.41
- Osteoarthritis, knee0.41
- Medical procedure0.39
- Lymphatic system disorder0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712856, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P24821, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets